KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Gross Margin (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Gross Margin data on record, last reported at 88.88% in Q2 2025.

  • For Q2 2025, Gross Margin fell 38.0% year-over-year to 88.88%; the TTM value through Jun 2025 reached 117.48%, up 2809.0%, while the annual FY2025 figure was 88.21%, 84.0% down from the prior year.
  • Gross Margin reached 88.88% in Q2 2025 per JAZZ's latest filing, up from 88.17% in the prior quarter.
  • Across five years, Gross Margin topped out at 93.39% in Q1 2021 and bottomed at 82.67% in Q3 2021.
  • Average Gross Margin over 5 years is 87.39%, with a median of 88.17% recorded in 2024.
  • Peak YoY movement for Gross Margin: tumbled -1012bps in 2021, then surged 662bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 84.82% in 2021, then decreased by -2bps to 82.78% in 2022, then grew by 8bps to 89.4% in 2023, then fell by -1bps to 88.17% in 2024, then increased by 1bps to 88.88% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 88.88% in Q2 2025, 88.17% in Q4 2024, and 89.42% in Q3 2024.